Candel Therapeutics, Inc.
CADL Healthcare Biotechnology
Candel Therapeutics, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $125,000.00. In the quarter to June 2026, EPS fell 477.8%, free cash flow fell 93.4% and total debt rose 525.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow CADL
Candel Therapeutics, Inc. (CADL) EV/Sales
As of 16 October 2026, Candel Therapeutics, Inc. (CADL) trades at a EV/Sales of 3,661×. Over the past ten years it has ranged from −106× (December 2022) to 6,958× (August 2026); the current reading is higher than 94% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2022 | 18.2× | (96.55%) |
| FY2021 | 528× | 11.46% |
| FY2020 | 473× | 0.00% |
| FY2019 | 473× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2022 | 18.2× | (93.45%) |
| Sep 2022 | 278× | 25.71% |
| Jun 2022 | 221× | (61.97%) |
| Mar 2022 | 581× | 10.15% |
| 7 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| AURA Aura Biosciences, Inc. compare | n/m |
| ANNX Annexon, Inc. compare | n/m |
| PHAR Pharming Group N.V. Sponsored ADR compare | 1.2× |
| MDXG MiMedx Group, Inc compare | 1.5× |
| GYRE Gyre Therapeutics, Inc. compare | 4.7× |
| OABI OmniAb, Inc. compare | 14.0× |
| PRME Prime Medicine, Inc. compare | 128× |
| DSGN Design Therapeutics, Inc. compare | 1,934× |
| CADL Candel Therapeutics, Inc. | 3,661× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)